BioLight to Distribute Laser Eye Surgery System in Hong Kong, Macao
BioLight Life Sciences Investments Ltd. will distribute IOPtima’s IOPtiMate laser eye surgery system in Hong Kong and Macao, with a purchase commitment of at least nine systems.
IOPtiMate is based on CO
2 laser technology and enables filtration surgery, which treats glaucoma without penetrating the inner part of the eyeball. Compared with alternatives, this allows substantial reductions in postoperative complications and use of eye drops, according to BioLight.
A leading medical center in Hong Kong recently purchased the system, while another is using IOPtiMate on a trial basis.
“Entering into a strategic distribution agreement in Hong Kong and Macao is an additional significant advancement in our plan to penetrate developing markets in Asia, where there is no available solution for a large population of patients,” said BioLight CEO Suzana Nahum-Zilberberg.
Earlier this year BioLight and IOPtima reached a distribution agreement for China with a purchase commitment of 100 systems.
For more information, visit
www.bio-light.co.il.
LATEST NEWS
- Exail Signs LLNL Contract, Partners with Eelume
Apr 26, 2024
- Menlo Moves U.S. HQ: Week in Brief: 4/26/2024
Apr 26, 2024
- Optofluidics Platform Keys Label-, Amplification-Free Rapid Diagnostic Tool
Apr 25, 2024
- DUV Lasers Made with Nonlinear Crystals Enhance Lithography Performance
Apr 25, 2024
- Teledyne e2v, Airy3D Collaborate on 3D Vision Solutions
Apr 24, 2024
- One-Step Hologram Generation Speeds 3D Display Creation
Apr 24, 2024
- Innovation Award Winners for Laser Technology Honored in Aachen
Apr 23, 2024
- Intech 2024: AI Arrives on the Shop Floor
Apr 22, 2024